1. Home
  2. DUOL vs IONS Comparison

DUOL vs IONS Comparison

Compare DUOL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Duolingo Inc.

DUOL

Duolingo Inc.

SELL

Current Price

$168.76

Market Cap

6.3B

Sector

Technology

ML Signal

SELL

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$28.01

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUOL
IONS
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.6B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
DUOL
IONS
Price
$168.76
$28.01
Analyst Decision
Hold
Buy
Analyst Count
24
25
Target Price
★ $153.93
$68.48
AVG Volume (30 Days)
1.4M
★ 4.2M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 355.85
21.71
EPS
★ 2.08
N/A
Revenue
★ $1,037,589,000.00
N/A
Revenue This Year
$17.76
N/A
Revenue Next Year
$14.13
$32.51
P/E Ratio
$79.86
★ N/A
Revenue Growth
★ 38.71
N/A
52 Week Low
$87.89
$27.25
52 Week High
$213.37
$86.74

Technical Indicators

Market Signals
Indicator
DUOL
IONS
Relative Strength Index (RSI) 64.20 22.61
Support Level $97.86 N/A
Resistance Level N/A $46.07
Average True Range (ATR) 9.91 2.07
MACD 2.90 -1.18
Stochastic Oscillator 91.96 7.56

Price Performance

Historical Comparison
DUOL
IONS

About DUOL Duolingo Inc.

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: